dm+d

Unassigned

New Medicines

Information

New molecular entity
Pfizer
Pfizer

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Inhibitor of p38 mitogen-activated protein (MAP) kinase. Dosed at 400mg twice daily.
It is difficult to know the true prevalence but it is estimated at around 1 in 2,500. Genetic inheritance arises in 35% of patients. Mutations in 60 genes have been associated with dilated cardiomyopathy [1]. Lamin A/C gene is among the most common cardiomyopathy-causing gene. Cardiomyopathies induced by these mutations have a very aggressive and fast clinical course that could culminate with sudden cardiac death from malignant ventricular arrhythmias and end-stage heart failure [2].
Dilated cardiomyopathy due to lamin A/C gene mutations (LMNA-related DCM) - first-line in adults
Oral